New schizophrenia drug injection shows promise in bioequivalence trial

NCT ID NCT07268430

Completed Disease control Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a new paliperidone palmitate injection works the same as the standard one in 256 Chinese patients with schizophrenia. Patients received either the new or the standard injection, and researchers measured drug levels in the blood to see if they matched. The goal was to show the new version is equivalent, which could lead to more treatment options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: paliperidone palmitate injection
What this could lead to: If successful, this could show that the new injection is equivalent to the existing one, potentially offering a more affordable or accessible treatment option for schizophrenia.
What could go wrong: This is a bioequivalence study, not a test of effectiveness. It only checks if the drug levels in the blood match the reference product. The trial is completed, but results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

Beijing Anding Hospital Capital Medical University

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.